Stockscreener 앱 받기
0.00
100.00%
-0.55
전일 마감가:
$0.55
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$30.37M
수익:
$30.99M
순이익/손실:
$-141.41M
주가수익비율:
0.00
EPS:
-2.63
순현금흐름:
$-118.12M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$9.41
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
명칭
Marinus Pharmaceuticals Inc
전화
484-801-4670
주소
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
MRNS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.00 | 30.37M | 30.99M | -141.41M | -118.12M | -2.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.18 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
662.62 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
613.04 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.54 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.59 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-08-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-04-16 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-04-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-01-20 | 개시 | RBC Capital Mkts | Outperform |
| 2020-09-30 | 개시 | Truist | Buy |
| 2020-07-01 | 개시 | Cowen | Outperform |
| 2020-07-01 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-09 | 개시 | Craig Hallum | Buy |
| 2019-12-20 | 개시 | Oppenheimer | Outperform |
| 2019-03-05 | 재개 | Jefferies | Buy |
| 2019-02-27 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-02-06 | 개시 | Leerink Partners | Outperform |
| 2018-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-03-20 | 개시 | Mizuho | Buy |
| 2018-02-15 | 개시 | H.C. Wainwright | Buy |
| 2017-12-14 | 개시 | Laidlaw | Buy |
| 2016-08-10 | 재확인 | Jefferies | Buy |
| 2016-06-14 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-03-08 | 재확인 | Stifel | Buy |
| 2015-12-17 | 개시 | RBC Capital Mkts | Outperform |
| 2015-11-17 | 개시 | Jefferies | Buy |
| 2015-10-30 | 재확인 | Oppenheimer | Outperform |
| 2015-08-05 | 재확인 | Oppenheimer | Outperform |
모두보기
Marinus Pharmaceuticals Inc 주식(MRNS)의 최신 뉴스
Developmental and Epileptic Encephalopathies Treatment - openPR
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com - Armenian Reporter
MRNS LAWSUIT ALERT: Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNS - ACCESS Newswire
Long-Term Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: - openPR
StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Armenian Reporter
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Shareholders - ACCESS Newswire
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Marinus pharmaceuticals director sells shares for $864 - MSN
Marinus Pharmaceuticals director sells shares worth $869 - MSN
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock - MSN
Tuberous Sclerosis Complex Therapeutics Market Size Report - openPR
IMMINENT MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com - Defense World
Marinus Pharmaceuticals (NASDAQ:MRNS) Acquisition Completed by Immedica Pharma AB - Defense World
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock By Investing.com - Investing.com UK
Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals - TipRanks
Make Informed Decisions with Marinus Pharmaceuticals Inc (MRNS) Stock Updates - The News Heater
Taking on analysts’ expectations and winning: Marinus Pharmaceuticals Inc (MRNS) - SETE News
Marinus Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your RightsMRNS - ACCESS Newswire
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact Levi & Korsinsky about pending Class ActionMRNS - ACCESS Newswire
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Morgan Stanley's Strategic Acquisition of Marinus Pharmaceuticals Shares - GuruFocus.com
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Recommendation of “Hold” by Brokerages - Defense World
JPMorgan Chase & Co. Buys 126,752 Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Defense World
Vanguard Group Inc Reduces Holdings in Marinus Pharmaceuticals I - GuruFocus.com
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
UPCOMING MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Assenagon Asset Management S.A. - Defense World
Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis - MarketBeat
Marinus pharmaceuticals director sells shares for $864 By Investing.com - Investing.com Canada
Immedica to buy Marinus Pharmaceuticals for $151m - MSN
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene - Barchart
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, - openPR
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AE, MRNS, SASR, ROIC to Take Action - The Malaysian Reserve
Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints - MSN
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know - MSN
Beryl Capital Management LLC Acquires Significant Stake in Marin - GuruFocus.com
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of Shareholders - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Marinus Pharmaceuticals, Inc.MRNS - Kilgore News Herald
Immedica Pharma AB’s Acquisition of Marinus Pharmaceuticals - Global Legal Chronicle
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc.MRNS - Business Wire
Immedica acquires Marinus in $151 million deal - The Pharma Letter
Marinus Therapeutics in Radnor Acquired by Swedish Company - MSN
StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
Marinus Pharmaceuticals Inc (MRNS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.22%
0.27%
자본화:
|
볼륨(24시간):